Recent advances in novel radioimmunotherapeutic approaches
for allogeneic hematopoietic cell transplantation
Jaideep Shenoi, Ajay K. Gopal, Oliver W. Press and John M. Page
Purpose of review
Allogeneic hematopoietic cell transplantation (HCT) can be a curative treatment for
hematologic malignancies and over the last three decades, novel approaches have
resulted in significant reductions in morbidity and mortality. Despite current advances,
two major limitations remain: patients continue to die from recurrent disease, and rates
of nonrelapse mortality are relatively high due to regimen-related organ toxicities. The
ability to target therapy with radiolabeled antibodies provides an innovative way to
increase the tumoricidal dose of radiation to tumor sites, whereas sparing normal
organs, as further dose escalation of chemotherapy and radiotherapy in HCT
preparative regimens is not feasible due to dose-limiting toxicities.
This review discusses the most current allogeneic HCT data using radioimmunotherapy
(RIT) and focuses on recent trials involving patients at the highest risk for relapse. The
results from these studies have shown that standard-dose radiolabeled antibodies can
be safely combined with reduced-intensity preparative regimens with encouraging
results in a single institution phase II study.
Optimism remains that these RIT approaches will improve the cure rates of allogeneic
HCT for the thousands of patients with leukemias and lymphomas who undergo this
procedure each year.
allogeneic hematopoietic cell transplant, leukemia, lymphoma, radioimmunotherapy,
Curr Opin Oncol 22:143–149
The complete pdf on johnite.org